Study of Dapagliflozin to Reduce Heart Damage in Adults with STEMI Undergoing PPCI

What this Trial Is About

Researchers are evaluating the safety and effectiveness of dapagliflozin, a type of SGLT2 inhibitor, in reducing the size of heart damage in patients who have experienced a ST Elevation Myocardial Infarction STEMI and are undergoing primary percutaneous coronary intervention PPCI. This randomized, double-blind, phase 3 clinical trial compares dapagliflozin with a placebo to better understand its impact on heart tissue after a heart attack. Participants will be randomly assigned to receive either dapagliflozin 10 mg or a placebo once daily for 7 days. Cardiac Magnetic Resonance CMR imaging will be performed 3 to 5 days after treatment begins to measure the size of the heart injury. Follow-up visits will occur at 30, 90, and 180 days to monitor cardiovascular events and other health outcomes. During the study, participants will undergo CMR scans, regular cardiovascular assessments, and safety monitoring, including checks for kidney function and heart complications. Researchers will track the size of the infarct and record any serious cardiac events, cardiogenic shock during hospitalization, and acute kidney injury. The total participation time includes the initial 7-day treatment period and follow-ups extending up to 6 months.

Dapagliflozin in STEMI